Artivion Inc
NYSE:AORT

Watchlist Manager
Artivion Inc Logo
Artivion Inc
NYSE:AORT
Watchlist
Price: 28.55 USD 0.95% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Artivion Inc?
Write Note

Artivion Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Artivion Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Artivion Inc
NYSE:AORT
Other Long-Term Assets
$10m
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Long-Term Assets
$2.6B
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Other Long-Term Assets
$4.5B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
28%
Stryker Corp
NYSE:SYK
Other Long-Term Assets
$3.9B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Other Long-Term Assets
$8B
CAGR 3-Years
26%
CAGR 5-Years
28%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Long-Term Assets
$1.6B
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
28%
No Stocks Found

Artivion Inc
Glance View

Market Cap
1.2B USD
Industry
Health Care

In the heart of the biomedical landscape, Artivion Inc. emerges as a company fervently dedicated to extending and saving lives through advanced medical technologies. It is a principal innovator and supplier in cardiac and vascular surgery, carving its niche by providing unique products that serve critical therapeutic needs. Initially branded as CryoLife, the company redefined its mission and vision under the Artivion name post a strategic transformation, focusing on strategically enhancing its product portfolio. It crafts precision-engineered prosthetic heart valves, notably the On-X mechanical valve, which is renowned for its exceptional long-term durability and performance in reducing the need for anticoagulation therapy. Through its relentless innovation, Artivion ensures that its offerings are not only of high quality but also cost-effective, thereby widening the accessibility to life-saving technologies. This commitment to quality is underscored by their rigorous research and development efforts and regulatory compliance, ensuring every product meets global medical standards. Artivion's revenue engine is driven largely by its cardiovascular implantables and bioprosthetics used in vascular surgery, alongside tissue processing services that provide mitral, aortic, and pulmonary cardiac valves. By coupling advanced materials and sophisticated design, the organization enhances its presence in the global cardiovascular industry—serving hospitals, physicians, and patients alike. Its products are distributed through a combination of direct sales and distributor partnerships, broadening its geographical market presence from the United States to Europe, Asia, and beyond. Artivion stands not only as a supplier but as a strategic partner to clinicians, extending support and education to ensure optimal patient outcomes. Its strategic prowess in the competitive med-tech arena is an intricate mosaic of innovation, operational excellence, and a keen awareness of the pressing health challenges that afflict the global population. Through these concerted efforts, Artivion not only sustains its growth and shareholder value but continues its mission to improve life expectancy and quality around the world.

AORT Intrinsic Value
23.23 USD
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Artivion Inc's Other Long-Term Assets?
Other Long-Term Assets
10m USD

Based on the financial report for Dec 31, 2023, Artivion Inc's Other Long-Term Assets amounts to 10m USD.

What is Artivion Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-4%

Over the last year, the Other Long-Term Assets growth was 15%. The average annual Other Long-Term Assets growth rates for Artivion Inc have been -15% over the past three years , -4% over the past five years .

Back to Top